390 related articles for article (PubMed ID: 30143249)
41. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures.
Passot G; Vaudoyer D; Villeneuve L; Kepenekian V; Beaujard AC; Bakrin N; Cotte E; Gilly FN; Glehen O
J Surg Oncol; 2016 Jun; 113(7):796-803. PubMed ID: 27110915
[TBL] [Abstract][Full Text] [Related]
42. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for limited peritoneal metastasis. The PSOGI international collaborative registry.
Arjona-Sanchez A; Aziz O; Passot G; Salti G; Esquivel J; Van der Speeten K; Piso P; Nedelcut DS; Sommariva A; Yonemura Y; Turaga K; Selvasekar CR; Rodriguez-Ortiz L; Sanchez-Hidalgo JM; Casado-Adam A; Rufian-Peña S; Briceño J; Glehen O
Eur J Surg Oncol; 2021 Jun; 47(6):1420-1426. PubMed ID: 33298341
[TBL] [Abstract][Full Text] [Related]
43. Iterative procedures combining cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for isolated peritoneal recurrence.
Vaira M; Robella M; Mellano A; Sottile A; De Simone M
Int J Hyperthermia; 2014 Dec; 30(8):565-9. PubMed ID: 25430988
[TBL] [Abstract][Full Text] [Related]
44. Skeletal Muscle Depletion is Associated with Severe Postoperative Complications in Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Cancer.
van Vugt JL; Braam HJ; van Oudheusden TR; Vestering A; Bollen TL; Wiezer MJ; de Hingh IH; van Ramshorst B; Boerma D
Ann Surg Oncol; 2015 Oct; 22(11):3625-31. PubMed ID: 25672564
[TBL] [Abstract][Full Text] [Related]
45. Recurrence after cytoreductive surgery and HIPEC for pseudomyxoma peritonei: A single-center retrospective cohort study.
Yrjönen A; Koskenvuo L; Haapamäki C; Lepistö A
Scand J Surg; 2024 Jun; 113(2):140-149. PubMed ID: 37828760
[TBL] [Abstract][Full Text] [Related]
46. Preoperative nutritional risk assessment in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for colorectal carcinomatosis.
Banaste N; Rousset P; Mercier F; Rieussec C; Valette PJ; Glehen O; Passot G
Int J Hyperthermia; 2018 Aug; 34(5):589-594. PubMed ID: 28828897
[TBL] [Abstract][Full Text] [Related]
47. Analysis of causes and prognostic impact of tube occlusion during hyperthermic intraperitoneal chemotherapy for appendiceal pseudomyxoma peritonei.
Liu Q; Jiao J; Li C; Chen Y; Wang B; Shi J; Yu G
World J Surg Oncol; 2024 May; 22(1):134. PubMed ID: 38769546
[TBL] [Abstract][Full Text] [Related]
48. Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study.
Malgras B; Gayat E; Aoun O; Lo Dico R; Eveno C; Pautrat K; Delhorme JB; Passot G; Marchal F; Sgarbura O; Ferron G; Goéré D; Andre T; Pocard M;
Ann Surg Oncol; 2018 Oct; 25(11):3271-3279. PubMed ID: 29978366
[TBL] [Abstract][Full Text] [Related]
49. Two-step cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei with high peritoneal carcinomatosis index.
Trilling B; Brind'Amour A; Hamad R; Tremblay JF; Dubé P; Mitchell A; Sidéris L
World J Surg Oncol; 2021 Feb; 19(1):60. PubMed ID: 33622339
[TBL] [Abstract][Full Text] [Related]
50. Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience.
Narasimhan V; Wilson K; Britto M; Warrier S; Lynch AC; Michael M; Tie J; Akhurst T; Mitchell C; Ramsay R; Heriot A
J Gastrointest Surg; 2020 Apr; 24(4):899-906. PubMed ID: 31090036
[TBL] [Abstract][Full Text] [Related]
51. A proposal of Brazilian Society of Surgical Oncology (BSSO/SBCO) for standardizing cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma.
Batista TP; Sarmento BJQ; Loureiro JF; Petruzziello A; Lopes A; Santos CC; Quadros CA; Akaishi EH; Cordeiro EZ; Coimbra FJF; Laporte GA; Castro LS; Batista RMSS; Aguiar S; Costa WL; Ferreira FO;
Rev Col Bras Cir; 2017; 44(5):530-544. PubMed ID: 29019584
[TBL] [Abstract][Full Text] [Related]
52. The Impact of Low Skeletal Muscle Mass on Short- and Long-Term Outcomes After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Dietz MV; van Kooten JP; van Vugt JLA; Brandt-Kerkhof ARM; Verhoef C; Madsen EVE
Ann Surg Oncol; 2022 Sep; 29(9):5830-5841. PubMed ID: 35650370
[TBL] [Abstract][Full Text] [Related]
53. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?
López-López V; Cascales-Campos PA; Gil E; Arevalo J; Gonzalez A; Gil J; Muñoz-Casares FC; Melero JT; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Parrilla P
Clin Transl Oncol; 2017 Nov; 19(11):1388-1392. PubMed ID: 28812240
[TBL] [Abstract][Full Text] [Related]
54. Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival.
Verma V; Sleightholm RL; Rusthoven CG; Koshy M; Sher DJ; Grover S; Simone CB
Ann Surg Oncol; 2018 Jul; 25(7):2018-2026. PubMed ID: 29721724
[TBL] [Abstract][Full Text] [Related]
55. Development and Validation of Nomograms to Predict Survival in Patients Undergoing Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendiceal Origin.
Chandrakumaran K; Carr NJ; Mohamed F; Cecil TD; Moran BJ
JAMA Surg; 2023 May; 158(5):522-530. PubMed ID: 36920381
[TBL] [Abstract][Full Text] [Related]
56. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
57. Outcomes of cytoreductive surgery and HIPEC for pseudomyxoma peritonei of appendiceal origin from two Indian centers: A preliminary five-year experience.
Bhatt A; Sheshadri D; Chandan G; Ramaswamy V; Pandey J; Bhorkar N; Agrawal D; Mehta S
J BUON; 2017; 22(1):251-257. PubMed ID: 28365962
[TBL] [Abstract][Full Text] [Related]
58. Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) in the treatment of pseudomyxoma peritonei: ten years experience in a single center.
Deraco M; Kusamura S; Laterza B; Favaro M; Fumagalli L; Costanzo P; Baratti D
In Vivo; 2006; 20(6A):773-6. PubMed ID: 17203766
[TBL] [Abstract][Full Text] [Related]
59. Peritoneal Spread of Low-grade Appendiceal Tumours - 2 Days of Early Postoperative Intra-peritoneal Chemotherapy Are Enough.
Rao A; Mui J; Barat S; Matar AA; Alzahrani N; Morris DL
Anticancer Res; 2021 Nov; 41(11):5569-5575. PubMed ID: 34732427
[TBL] [Abstract][Full Text] [Related]
60. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes.
Deban M; Taqi K; Knapp GC; Soucisse M; Curry M; Sidéris L; Dubé P; Khaldi MA; Jedrzejko N; Porter G; Giacomantonio C; Hamilton T; MacNeill A; Mack L; Bouchard-Fortier A
J Surg Oncol; 2023 Sep; 128(4):595-603. PubMed ID: 37249154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
